Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA). ClinicalTrials.gov, Verified December 2014 by Weill Medical College of Cornell University
ClinicalTrials.gov identifier: NCT02316314
Sponsors and Collaborators: Weill Medical College of Cornell University
Principal Investigator: Ronald Crystal, MD
Thursday, December 18, 2014
Assembly of Fe/S proteins in bacterial systems ☆: Biochemistry of the bacterial ISC system
Assembly of Fe/S proteins in bacterial systems ☆: Biochemistry of the bacterial ISC system. B. Blanc, C. Gerez, S. Ollagnier de Choudens; Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, Available online 13 December 2014, ISSN 0167-4889, http://dx.doi.org/10.1016/j.bbamcr.2014.12.009.
Tuesday, December 16, 2014
Terapia ocupacional en ataxia de friedreich
Terapia ocupacional en ataxia de friedreich. Ana Cristina Martín Pérez, Dolores Moreno Antequera; Revista electrónica de terapia ocupacional Galicia, TOG, ISSN-e 1885-527X, Nº. 20 (Noviembre), 2014
Occupational therapy in friedreich ataxia (Paper in Spanish)
The objective of this article is to present management "Framework for the practice of occupational therapy (domains and processes) and contrast their utility for assessment, diagnosis and intervention in the area of basic and instrumental activities of daily living daily, leisure time and social participation
FULL TEXT PDF
Occupational therapy in friedreich ataxia (Paper in Spanish)
The objective of this article is to present management "Framework for the practice of occupational therapy (domains and processes) and contrast their utility for assessment, diagnosis and intervention in the area of basic and instrumental activities of daily living daily, leisure time and social participation
FULL TEXT PDF
Iron Metabolism and Related Disorders
Iron Metabolism and Related Disorders. K. Hoda, C.L. Bowlus, T.W. Chu and J.R. Gruen, In Reference Module in Biomedical Sciences, Elsevier, 2014, Current as of 1 December 2014, ISBN 9780128012383, http://dx.doi.org/10.1016/B978-0-12-801238-3.05573-2.
Fast-Tracking the Development of Effective Therapeutics in Mitochondrial Medicine
Fast-Tracking the Development of Effective Therapeutics in Mitochondrial Medicine. S P Hersh, Clinical Pharmacology & Therapeutics (2014); 96 6, 641–643. doi:10.1038/clpt.2014.163.
Saturday, December 13, 2014
Helix–Coil Transition Induced by Metal Ion Interaction with a Grafted Iron–Binding Site of the CyaY Protein Family
Helix–Coil Transition Induced by Metal Ion Interaction with a Grafted Iron–Binding Site of the CyaY Protein Family. Diego Sebastián Vazquez, William Armando Agudelo, Angel Yone, Nora Vizioli, Martín Arán, Luis Gonzalez Flecha, Mariano Camilo González Lebrero and Javier Santos; Dalton Trans., 2014,
DOI: 10.1039/C4DT02796E
These results contribute to an understanding of the iron–binding mechanisms in proteins and, in particular, in the case of human frataxin.
DOI: 10.1039/C4DT02796E
These results contribute to an understanding of the iron–binding mechanisms in proteins and, in particular, in the case of human frataxin.
Friday, December 12, 2014
Protecting the mitochondrial powerhouse
Protecting the mitochondrial powerhouse. Morten Scheibye-Knudsen, Evandro F. Fang, Deborah L. Croteau, David M. Wilson III, Vilhelm A. Bohr; Trends in Cell Biology, Available online 11 December 2014, ISSN 0962-8924, http://dx.doi.org/10.1016/j.tcb.2014.11.002.
Keywords: mitochondria; DNA repair; mitophagy; reactive oxygen species; disease
Keywords: mitochondria; DNA repair; mitophagy; reactive oxygen species; disease
Thursday, December 11, 2014
Principled compassion, 'right to try'
Principled compassion, 'right to try' . Editorial, Nature Medicine 20, 1355 (2014) doi:10.1038/nm.3772
As the momentum of right-to-try legislation demonstrates, the public increasingly demands access to the compassionate use of investigational treatments, and companies and regulators need to adapt to this new reality.
As the momentum of right-to-try legislation demonstrates, the public increasingly demands access to the compassionate use of investigational treatments, and companies and regulators need to adapt to this new reality.
A methodological framework for drug development in rare diseases
A methodological framework for drug development in rare diseases. Patrice Nony, Polina Kurbatova, Agathe Bajard, Salma Malik, Charlotte Castellan, Sylvie Chabaud, Vitaly Volpert, Nathalie Eymard, Behrouz Kassai, Catherine Cornu and The CRESim and Epi-CRESim study groups; Orphanet Journal of Rare Diseases 2014, 9:164 doi:10.1186/s13023-014-0164-y
OPEN ACCES, FULL TEXT PDF
OPEN ACCES, FULL TEXT PDF
Wednesday, December 10, 2014
Monitoring Cardiac Function During Idebenone Therapy in Friedreich's Ataxia
Monitoring Cardiac Function During Idebenone Therapy in Friedreich's Ataxia. Di Salvo Giovanni, Pergola Valeria, Fadel Bahaa and Al Fayyadh Majid; Curr Pharm Des. 2014;21(4):479-83. DOI: 10.2174/138161282104141204142917
Subscribe to:
Posts (Atom)
